Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients

AIDS

Volumn 24, Issue 16, 2010, Pages 2581-2583

  Barrail Tran, Aurélie ^a,b   Yazdanpanah, Yazdan ^a,c   Goldwirt, Lauriane ^a,b   Chêene, Geneviéve ^a,d   Colin, Céiine ^a,d   Piketty, Christophe ^a,e   Bollens, Diane ^a,f   Katlama, Christine ^a,g   Descamps, Diane ^a,h   Molina, Jean Michel ^a,i   Fagard, Catherine ^a,d   Taburet, Anne Marie ^a,b  

^a ANRS 139 Study Group   (France)

^b BICÊTRE HOSPITAL   (France)

^c University Hospital of Tourcoing   (France)

^d INSERM   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h BICHAT HOSPITAL   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; ETRAVIRINE; RALTEGRAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QUESTIONNAIRE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT FAILURE; VIRUS HEPATITIS;

ADOLESCENT; ADULT; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; RITONAVIR; SULFONAMIDES; YOUNG ADULT;

EID: 78549245842     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833d89fa     Document Type: Article

References (11)

1. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009;49:1441-1449.
2. Goldwirt L, Barrail-Tran A, Da Cruz M, Taburet AM, Furlan V. Quantification of raltegravir (MK 0518) in human plasma by high-performance liquid chromatography with photodiode array detection. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:456-460.
3. Boffito M, Winston A, Jackson A, Fletcher C, Pozniak A, Nelson M, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007; 21:1449-1455.
4. Anderson MS, Kakuda TN, Hanley W, Miller J, Kost JT, Stoltz R, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008;52: 4228-232.
5. Scholler-Gyure M, Kakuda TN, Raoof A, De Smedt G, Hoetelmans RM. Clinical pharmacokinetics and pharma- codynamics of etravirine. Clin Pharmacokinet 2009; 48:561-574.
6. Scholler-GyureM, Kakuda TN, Sekar V, Woodfall B, De Smedt G, Lefebvre E, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007;12:789-796.
7. Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimi- crob Agents Chemother 2009; 53:2852-2856.
8. Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2008; 52:3253-3258.
9. Menard A, Solas C, Mokthari S, Bregigeon S, Drogoul MP, Tamalet C, et al. Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases. AIDS 2009; 23:869-871.
10. Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008; 83:293-299.
11. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, et al. Antiretroviral activity, phar- macokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43:509-515.